Uso de glifozinas y finerenona en pacientes con diabetes mellitus tipo 2 portadores de enfermedad renal crónica

Abstract

Chronic kidney disease (CKD) and diabetes mellitus (DM) as co-existing diseases have grown proportionally in prevalence and, therefore, need to be highlighted as a priority global health concern due to their associated increased risk of mortality. DM is one of the main causes of CKD, affecting approximately 40% of adults diagnosed with this pathology. DM is characterized by chronic hyperglycaemia, which can lead to vascular complications, including diabetic nephropathy, and can progress to end-stage renal disease, so adequate glycemic control is significant, as well as a comprehensive management in preventing and treating these patients. Finerenone is presented as a new drug approved for treating CKD with albuminuria linked to type 2 DM, highlighting its mechanism of action and pharmacological differences with other medications, besides the benefits of sodium-glucose cotransporter 2 (iSGLT2) inhibitors in managing type 2 DM and their impact on preventing progression of CKD. The importance of a comprehensive and multidisciplinary approach in managing patients with DM and CKD is also addressed, as well as the need for future research to examine the efficacy of combining therapy with Finerenone and iSGLT2 in CKD.